ENTtoday

Randomized Trial Shows No Benefit of Intra-Arterial Chemoradiation Delivery in Head and Neck Cancer

by Rabiya S. Tuma, PhD •

In fact, a reduction in side effects was the one area in which Dr. Rasch’s group found significant differences between the two trial arms. Only 1% of patients in the IA arm had renal toxicity as a result of therapy, compared with 10% in the IV arm. Also, patients in the IA arm had less trouble with nausea and vomiting. On the other hand, 9% of IA patients had neurological toxicity, compared with just 1% in the IV arm.

For Dr. Robbins, other benefits far outweigh the risk of neurological toxicity-particularly because most patients recover from neurological complications in both his experience and in the Dutch trial.

©2007 The Triological Society